TRVI Stock Overview
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Trevi Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.54 |
| 52 Week High | US$4.00 |
| 52 Week Low | US$0.97 |
| Beta | 0.87 |
| 1 Month Change | -25.07% |
| 3 Month Change | 62.82% |
| 1 Year Change | -25.73% |
| 3 Year Change | 8.09% |
| 5 Year Change | n/a |
| Change since IPO | -67.81% |
Recent News & Updates
Recent updates
Shareholder Returns
| TRVI | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -5.4% | 0.08% | 1.2% |
| 1Y | -25.7% | 13.2% | 24.9% |
Return vs Industry: TRVI underperformed the US Pharmaceuticals industry which returned 13.2% over the past year.
Return vs Market: TRVI underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| TRVI volatility | |
|---|---|
| TRVI Average Weekly Movement | 12.3% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TRVI's share price has been volatile over the past 3 months.
Volatility Over Time: TRVI's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 25 | Jennifer Good | www.trevitherapeutics.com |
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation.
Trevi Therapeutics, Inc. Fundamentals Summary
| TRVI fundamental statistics | |
|---|---|
| Market cap | US$175.16m |
| Earnings (TTM) | -US$29.06m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-6.0x
P/E RatioIs TRVI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TRVI income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$29.07m |
| Earnings | -US$29.06m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.42 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did TRVI perform over the long term?
See historical performance and comparison